


#NEVERMIND

ABOUT US | ACHIEVEMENTS | CONTACT US

June 2021


#NEVERMIND is a FRRB granted project coordinated by IRCCS Fondazione Don Carlo Gnocchi to develop **engineered nanovectors** to ameliorate the efficacy of drugs for neurodegenerative diseases and brain cancer.



SMALL ORGANIC MOLECULES

The laboratory of *Prof. Pierfausto Seneci of the University of Milan* illustrates us the extraordinary potential of **small molecules**, both synthetic and natural, in the fight against cancer and neurodegenerative disorders.

[read more](#)



ADVANCES IN ALZHEIMER'S DRUG DISCOVERY

This month, the Food and Drug Administration (FDA) approved the first new drug for **Alzheimer's disease**. Its name is **Aducanumab** and is developed by Biogen in Cambridge, Massachusetts. Despite controversies, this is a milestone in the treatment of Alzheimer's disease.

[read more](#)

News

INTERVIEW IN MI-TOMORROW

On 25th June, MiTomorrow published an interview with Dr. Bedoni and Dr. Gualerzi, coordinator and senior researcher of LABION, about the role of WOMEN in SCIENCE in Italy.

Read the interview on the [journal website](#) (Italian)

WHO WE ARE

This newsletter will bring you in the laboratories involved in the project. Every month insights about cutting-edge research topics and current events

Did you miss our previous newsletter? [click here](#)

Would you like to know more about a specific scientific topic?

Contact us, we will do our best to include it in the future newsletter

Find Us On Social Network:



labion@dongnocchi.it



@labion.eu



@labion_



@nevermind_frrb



www.labion.eu